标题
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
作者
关键词
-
出版物
Frontiers in Oncology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-05-03
DOI
10.3389/fonc.2021.672612
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
- (2021) Cristina Valero et al. Nature Communications
- Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
- (2020) Daan P. Hurkmans et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers
- (2020) Stephanie L. Guerra et al. CANCER CELL
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- (2020) Alex Friedlaender et al. CANCER TREATMENT REVIEWS
- Current therapy of KRAS-mutant lung cancer
- (2020) Aron Ghimessy et al. CANCER AND METASTASIS REVIEWS
- RAS-targeted therapies: is the undruggable drugged?
- (2020) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- KRAS: From undruggable to a druggable Cancer Target
- (2020) Dipesh Uprety et al. CANCER TREATMENT REVIEWS
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations
- (2020) Timothy F. Burns et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
- (2019) Badi El Osta et al. Journal of Thoracic Oncology
- Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
- (2019) Arnaud Jeanson et al. Journal of Thoracic Oncology
- Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
- (2019) Hyejin Choi et al. Cell Reports
- Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
- (2019) Jacqueline V. Aredo et al. LUNG CANCER
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
- (2019) Ghimessy et al. Cancers
- The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
- (2019) Chengming Liu et al. CANCER LETTERS
- Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
- (2019) David E. Gerber et al. LUNG CANCER
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer
- (2018) Enriqueta Felip et al. Journal of Thoracic Oncology
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
- (2018) Marta Román et al. Molecular Cancer
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
- (2018) Katsutoshi Sekine et al. LUNG CANCER
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
- (2018) Francesco Passiglia et al. BRITISH JOURNAL OF CANCER
- Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
- (2018) Ivana Yen et al. CANCER CELL
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
- (2017) Yi-Long Wu et al. LUNG CANCER
- STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
- (2016) S. Koyama et al. CANCER RESEARCH
- The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- (2016) Vassiliki Papadimitrakopoulou et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
- (2016) Tiffany G. Huynh et al. Journal of Thoracic Oncology
- XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
- (2016) Jimi Kim et al. NATURE
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
- (2015) S. Ramalingam et al. ANNALS OF ONCOLOGY
- Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells
- (2015) Hui Gao et al. CANCER LETTERS
- A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
- (2015) Felix Dietlein et al. CELL
- Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
- (2015) A. D. Cox et al. CLINICAL CANCER RESEARCH
- Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
- (2015) Antonio Calles et al. Journal of Thoracic Oncology
- Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial
- (2015) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
- (2015) Mirko Marabese et al. Oncotarget
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
- (2014) H. Koeppen et al. CLINICAL CANCER RESEARCH
- Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
- (2014) M. Macerelli et al. LUNG CANCER
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial
- (2013) G. R. Blumenschein et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers
- (2013) Jamie E. Chaft et al. Journal of Thoracic Oncology
- Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
- (2013) Gunther Zimmermann et al. NATURE
- RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
- (2013) Georgia Konstantinidou et al. Cancer Discovery
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- A solid phase extraction-liquid chromatographic–tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development
- (2011) X. Ding et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models
- (2010) Silvestre Vicent et al. JOURNAL OF CLINICAL INVESTIGATION
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- (2009) Martin L. Sos et al. JOURNAL OF CLINICAL INVESTIGATION
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
- (2008) C. Gridelli et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More